

## Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health

\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda.

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda.

\*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### Abstract

Human Immunodeficiency Virus (HIV) infection during pregnancy introduces a complex interplay between the maternal immune system and the imperative need for fetal development. This review delves into the nuanced relationship between maternal eosinophilic responses and HIV infection during pregnancy, offering insights into the immunological dynamics that influence both maternal and fetal outcomes. Eosinophils, traditionally associated with allergic responses, emerge as pivotal players in the adaptive immune responses of HIV-positive pregnant women. This abstract provides a succinct overview of the key themes explored in the review, emphasizing the implications of eosinophilic responses, potential roles in immune modulation, and the influence on vertical transmission risk. Further, it highlights the impact of antiretroviral therapy on maternal eosinophil dynamics, the delicate balance between immune tolerance and antiviral defenses, and the future perspectives and therapeutic implications that may optimize maternal-fetal health in the context of HIV.

**Keywords:** *Maternal immunology, eosinophils, HIV/AIDS, pregnancy, vertical transmission, immune modulation, antiretroviral therapy, immune tolerance, maternal-fetal health.*

### Introduction

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64

Human Immunodeficiency Virus (HIV) infection has profound implications for maternal health, and when intertwined with pregnancy, it introduces a unique set of challenges that extend beyond the conventional considerations of antiviral defenses.<sup>1-2</sup> HIV's impact on the immune system is multifaceted, and its consequences become particularly pronounced during pregnancy, a period marked by dynamic immunological adaptations to accommodate the developing fetus. Eosinophils, classically associated with parasitic infections and allergic responses, emerge as fascinating players in this complex scenario. These granulocytes, known for their role in modulating immune responses, bring a new dimension to the understanding of maternal-fetal immunology during HIV infection.<sup>3-7</sup>

The unique physiological demands of pregnancy necessitate an intricate dance between immune activation, immune tolerance, and antiviral defenses. In the context of HIV-positive pregnancies, this delicate balance becomes further complicated, raising questions about the role of eosinophils in orchestrating immune responses that both protect against viral transmission and foster a nurturing environment for fetal development. As we navigate these complexities, the following paragraphs aim to delve into the distinctive aspects of maternal eosinophilic responses, their potential modulation by HIV, and the implications for the overall well-being of both the mother and the developing fetus.<sup>8-21</sup>

## **Maternal Eosinophilic Responses**

Maternal eosinophilic responses during pregnancy have long been recognized as integral components of the complex immune orchestration necessary for fetal development. However, in the specific context of Human Immunodeficiency Virus (HIV) infection, these responses assume a multifaceted role that extends beyond conventional understanding. The immune system undergoes dynamic adaptations during pregnancy to accommodate the developing fetus. In the presence of HIV, this equilibrium is disrupted, prompting a reevaluation of the maternal immune responses. Eosinophils, as prominent effectors of the immune system, undergo modulation during pregnancy, potentially influenced by the presence of HIV. Understanding the intricacies of eosinophilic responses in this altered immune landscape is crucial for comprehending the immunopathogenesis of HIV/AIDS during gestation. Maternal-fetal tolerance is a hallmark of successful gestation, and eosinophils emerge as potential regulators of this delicate balance. These cells, traditionally associated with pro-inflammatory responses, exhibit immunomodulatory properties that may contribute to immune tolerance mechanisms during pregnancy. Unraveling the specific roles of eosinophils in maintaining maternal-fetal tolerance in the context of HIV represents a critical avenue for research, with implications for therapeutic interventions aimed at optimizing gestational outcomes.<sup>22-41</sup>

The risk of vertical transmission of HIV from mother to child remains a significant concern in affected pregnancies. Maternal eosinophilic responses may play a role in modulating this risk, influencing the efficiency of viral replication and transmission to the fetus. Exploring the intricate connections between eosinophils, viral dynamics, and vertical transmission rates is pivotal for

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

developing targeted interventions that may reduce the risk of perinatal HIV transmission. Antiretroviral therapy (ART) stands as a cornerstone in the management of HIV/AIDS during pregnancy. However, its impact on maternal eosinophilic responses remains a relatively unexplored territory. Understanding how ART influences the dynamics of eosinophils is essential, as it may shape both maternal immune responses and fetal development. Clarifying these interactions provides insights into optimizing therapeutic strategies and mitigating the potential immunological consequences of HIV and its treatment during pregnancy. Eosinophils, as components of the innate immune system, contribute to the first line of defense against pathogens. In the context of HIV, their modulation may extend beyond adaptive immune responses, influencing the broader innate immune landscape. Investigating the crosstalk between eosinophils and other innate immune components during HIV-infected pregnancies offers a holistic understanding of the maternal immune milieu, shedding light on potential targets for therapeutic interventions. Maternal eosinophilic responses in the context of HIV/AIDS contribute to the intricate immunopathogenesis of the disease during pregnancy. Recognizing the multifaceted roles of eosinophils unveils potential therapeutic targets. Strategies aimed at modulating eosinophilic responses, enhancing immune tolerance, and reducing vertical transmission risk emerge as promising avenues. These insights lay the groundwork for developing interventions that optimize maternal-fetal health, addressing the unique challenges posed by the coexistence of HIV and pregnancy.<sup>42-71</sup>

### **Vertical Transmission and Immune Modulation**

Maternal eosinophilic responses during HIV-positive pregnancies introduce a fascinating dimension to our understanding of the intricate immunological interplay between the mother and the developing fetus. Eosinophils, traditionally known for their involvement in allergic responses and parasitic infections, are increasingly recognized for their modulatory roles in shaping immune responses during gestation. Eosinophils, as granulocytes, are integral components of the innate immune system and have been historically studied in the context of parasitic infections and allergic reactions. However, their presence and function in the unique immunological milieu of pregnancy, especially in the context of HIV infection, remain relatively unexplored. Maternal eosinophilic responses extend beyond their classical roles, inviting inquiries into their potential modulatory effects on immune responses critical for both antiviral defenses and fetal development. Vertical transmission of HIV from mother to child remains a significant concern during pregnancy. Eosinophils, with their immunomodulatory functions, may influence the risk of vertical transmission by impacting viral replication and transmission dynamics. Understanding the potential modulation of vertical transmission risk by eosinophils opens avenues for targeted interventions aimed at reducing the likelihood of maternal-to-fetal viral transmission.<sup>72-91</sup>

The delicate balance between antiviral defenses and immune tolerance is paramount during pregnancy. Eosinophils, with their ability to modulate immune responses, may play a role in fostering immune tolerance crucial for successful gestation. This includes the need for the maternal immune system to tolerate the semi-allogeneic fetus while maintaining the ability to mount

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

effective antiviral defenses against HIV. Examining the contribution of eosinophils to immune tolerance offers insights into the immunological adaptations required for a healthy maternal-fetal interface in the presence of HIV. Antiretroviral therapy (ART) is a cornerstone in the management of HIV-positive pregnancies, significantly reducing the risk of vertical transmission. Exploring how eosinophils respond to ART and their potential modulation by these therapeutic regimens becomes crucial. The interaction between ART and eosinophilic responses may impact both the maternal immune milieu and the efficacy of viral control, influencing overall maternal and fetal health outcomes. Eosinophils do not operate in isolation; their functions are intertwined with other immune cells. Investigating the interplay between eosinophils and T cells, particularly CD4<sup>+</sup> T cells that are primary targets of HIV, provides a comprehensive understanding of how eosinophilic responses may influence the broader immunological landscape during HIV-positive pregnancies. The dynamic interactions between eosinophils and immune cell populations contribute to the complexity of maternal-fetal immunology in the context of HIV. Given the potential impact of eosinophils on immune modulation and vertical transmission risk, these cells emerge as intriguing biomarkers for assessing the immunological status of HIV-positive pregnant women. Furthermore, exploring eosinophils as therapeutic targets opens avenues for interventions aimed at optimizing maternal-fetal health outcomes. Strategies that leverage eosinophilic responses may enhance the efficacy of existing therapeutic regimens and contribute to the development of innovative approaches tailored to the unique immunological challenges presented by HIV-positive pregnancies.<sup>92-119</sup>

### **Antiretroviral Therapy and Eosinophil Dynamics**

Antiretroviral therapy (ART) has revolutionized the management of HIV/AIDS, playing a pivotal role in reducing viral loads, maintaining immune function, and preventing vertical transmission during pregnancy. Antiretroviral therapy serves as a cornerstone in controlling HIV replication and reducing maternal viral load. The effectiveness of ART in suppressing viral replication is a crucial determinant in minimizing the risk of vertical transmission. This section examines how the modulation of viral load through ART may influence eosinophil dynamics, exploring potential correlations between the degree of viral suppression and the modulation of eosinophilic responses. Beyond its direct antiviral effects, ART has immunomodulatory properties that influence the broader immune response. The impact of ART on eosinophil dynamics, including changes in their activation, proliferation, and functional capabilities, is an area of growing interest. Understanding the immunomodulatory effects of ART on eosinophils contributes to a comprehensive grasp of the therapy's influence on the maternal immune milieu. Achieving immune tolerance during pregnancy is essential for the success of gestation. ART, by modulating immune responses, may impact the delicate balance between effective antiviral defenses and the immune tolerance necessary for maternal-fetal health. Exploring how ART influences eosinophilic responses may unveil novel insights into its potential role in fostering immune tolerance mechanisms crucial for a healthy maternal-fetal interface.<sup>120-130</sup>

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

As ART contributes to immune restoration and suppression of viral replication, eosinophil dynamics may serve as indicators of the overall immune recovery process. Monitoring changes in eosinophil counts, activation markers, and functional profiles could offer valuable insights into the trajectory of immune reconstitution in HIV-positive pregnant women undergoing ART.<sup>131</sup> Eosinophils, as integral components of the immune system, reflect the broader immunological landscape shaped by therapeutic interventions. The interplay between eosinophils and other immune cells is complex and dynamic. ART's influence on T cells, particularly CD4+ T cells, is well-established, but its impact on the interactions between eosinophils and T cells remains an area ripe for exploration. Understanding how ART shapes the crosstalk between eosinophils and other immune cell populations contributes to a more comprehensive comprehension of the immunological effects of therapeutic interventions during pregnancy. The landscape of ART regimens is diverse, encompassing various drug classes and combinations. Investigating how different ART regimens influence eosinophil dynamics is crucial, considering potential variations in immunomodulatory effects. This section explores the nuances associated with different antiretroviral drugs and their potential differential impact on eosinophilic responses, guiding clinicians in tailoring therapeutic approaches for optimal maternal and fetal outcomes.

### **Immune Tolerance and Pregnancy Outcomes**

Achieving immune tolerance during pregnancy is a finely orchestrated process that involves intricate modulation of the maternal immune system to accommodate the semi-allogeneic fetus. In the context of HIV infection, this delicate balance becomes paramount, influencing not only the course of the maternal disease but also the outcomes of pregnancy. Pregnancy initiates a cascade of immunological changes aimed at establishing immune tolerance to the developing fetus.<sup>132</sup> These mechanisms include the expansion of regulatory T cells (Tregs), the modulation of cytokine profiles, and the creation of an anti-inflammatory environment. In the presence of HIV, these immune tolerance mechanisms become pivotal for maintaining a harmonious balance between antiviral defenses and the imperative need to tolerate fetal antigens. HIV, known for its ability to dysregulate the immune system, poses challenges to the establishment and maintenance of immune tolerance during pregnancy. The virus selectively targets CD4+ T cells, including Tregs, and induces chronic immune activation. This dual impact raises questions about the sustainability of immune tolerance mechanisms and their potential implications for pregnancy outcomes in HIV-positive women.

Eosinophils, traditionally associated with allergic responses, emerge as potential contributors to immune tolerance during pregnancy. Their regulatory functions, including the modulation of T cell responses and cytokine production, may play a role in fostering an environment conducive to fetal development. This section explores the nuanced involvement of eosinophils in immune tolerance mechanisms and their potential impact on pregnancy outcomes in the context of HIV infection. The compromised immune tolerance observed in HIV-positive pregnancies raises concerns about the potential for immune dysregulation and its impact on vertical transmission risk.<sup>134</sup> Understanding how alterations in immune tolerance mechanisms may influence the risk of

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

maternal-to-fetal transmission becomes crucial for refining therapeutic strategies and minimizing adverse pregnancy outcomes. Antiretroviral therapy (ART), while essential for viral suppression, may have implications for immune tolerance mechanisms. The potential modulation of Tregs, cytokine profiles, and other components of immune tolerance by ART raises questions about how therapeutic interventions influence the delicate balance required for successful pregnancy outcomes. This section explores the dual role of ART in viral control and immune modulation, aiming to delineate its impact on immune tolerance during HIV-positive pregnancies. The intricate interplay between maternal and fetal immune systems further complicates the dynamics of immune tolerance. Maternal-fetal crosstalk involves a delicate exchange of signals that influences the balance between immune activation and tolerance. How HIV disrupts this crosstalk and potentially impacts immune tolerance mechanisms remains a focal point for understanding pregnancy outcomes in HIV-positive women. Unraveling the complexities of immune tolerance and its impact on pregnancy outcomes in HIV-positive women holds implications for therapeutic interventions. Tailoring approaches to enhance immune tolerance while maintaining effective antiviral defenses becomes a pivotal consideration. This section explores potential avenues for interventions that leverage our understanding of immune tolerance mechanisms, aiming to optimize maternal-fetal health outcomes in the context of HIV infection.

## Conclusion

In unraveling the intricate interplay between maternal eosinophilic responses and HIV infection during pregnancy, this comprehensive exploration has illuminated a complex landscape of immunological dynamics. Eosinophils, often relegated to the sidelines in the broader context of maternal-fetal immunology, emerge as central players, influencing antiviral defenses, immune modulation, and the delicate balance required for successful gestation. As we draw conclusions from this journey, several key themes underscore the significance and potential implications for the clinical management of HIV-positive pregnant women. The potential modulation of vertical transmission risk by eosinophils unveils a novel perspective on their role in the prevention of maternal-to-fetal viral transmission. Insights into eosinophils' impact on viral replication and transmission dynamics open avenues for targeted interventions aimed at mitigating transmission risks. Understanding these dynamics contributes to refining strategies for reducing vertical transmission, a critical goal in the care of HIV-positive pregnant women.

## References

1. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine*. 2023;102(46):e36166.
2. 3D Human Tissue Models for HIV Working Group. 3D human tissue models and microphysiological systems for HIV and related comorbidities. *Trends in Biotechnology*. 2023.
3. Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. *Immunological reviews*. 2013;254(1):143-169.

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64



4. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
5. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
6. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
7. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
8. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
9. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
10. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
11. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
12. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
13. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
14. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
15. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-](https://doi.org/10.22192/ijcrms.2017.03.01.004)

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64

[OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](#)

16. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.  
[https://www.academia.edu/download/38320140/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
17. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138.  
<links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf>.
18. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8.  
<links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf>.
19. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 Apr;9(4):145-8. <links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf>.
20. Obeagu EI, Obeagu GU. Sick Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-3.  
<http://irmhs.com/index.php/irmhs/article/view/111>.
21. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.  
<links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf>.
22. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
23. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.  
<links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf>
24. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
25. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanjo CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA)

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64



and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.  
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://epjournals.com/journals/EJI/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).

26. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://epjournals.com/journals/EJI/links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf).
27. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
28. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://epjournals.com/journals/EJI/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
29. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
30. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
31. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://epjournals.com/journals/EJI/links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
32. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
33. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57>.
34. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-41.

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64

35. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2022;9(9):21-6.DOI: [10.22192/ijcrps.2022.09.09.003](https://doi.org/10.22192/ijcrps.2022.09.09.003)
36. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in pregnant women attending antenatal clinic in federal medical centre Owerri, Nigeria. *Madonna University Journal of Medicine and Health Sciences.* 2022;2(2):91-7. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67>.
37. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. *Journal of Research in Medical and Dental Science.* 2021;9(12):462-. [links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf](https://doi.org/10.22192/ijcrps.2022.09.09.003).
38. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Ironi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. *International Journal of Research and Reports in Hematology.* 2022 Jun 21;5(2):113-121.
39. Obeagu EI. Gestational Thrombocytopaenia. *J Gynecol Women's Health.* 2023;25(3):556163. [links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf](https://doi.org/10.22192/ijcrps.2022.09.09.003).
40. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
41. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-19.
42. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
43. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022;29-34.
44. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
45. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137.

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015).

46. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
47. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
48. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014) [https://www.academia.edu/download/54317126/Haematological indices of malaria pati ents coinfectd with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf)
49. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
50. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences.* 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
51. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137).
52. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
53. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal*

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

- of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211.  
<http://research.sdpublishers.net/id/eprint/2819/>.
54. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
  55. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
  56. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
  57. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
  58. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
  59. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160.  
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.researchgate.net/publication/311111111/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY/pdf).
  60. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
  61. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.researchgate.net/publication/341111111/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence/pdf).
  62. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obstetrics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.DOI: [10.22192/ijarbs.2023.10.03.016](https://doi.org/10.22192/ijarbs.2023.10.03.016)
  63. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-3. [links/64c890bddb38b20d6dad2c5c/PREGNANCY-](https://www.researchgate.net/publication/361111111/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH/pdf)

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64

[INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MATERNAL-AND-CHILD-HEALTH.pdf](#)

64. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-9.
65. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research*. 2017;5(4):206. [links/5ea97df145851592d6a8acf2/Iron-Status-of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf](#).
66. Eze RI, Obeagu EI, Edet FN. Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. *Madonna Uni J Med Health Sci*. 2021;1(1):19-30.
67. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. *J Pub Health Nutri*. 2023; 6 (1). 2023;137:26-35. [links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf](#).
68. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):14-7.DOI: 10.22192/ijcrms.2023.09.02.003
69. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(8):14-21.DOI: 10.22192/ijcreps.2023.10.08.002
70. Jakheng SP, Obeagu EI, Jakheng EW, Uwakwe OS, Eze GC, Obeagu GU, Vidya S, Kumar S. Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *International Journal of Research and Reports in Gynaecology*. 2022;5(3):98-105.
71. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. *Int. J. Curr. Res. Biol. Med*. 2018;3(9):1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
72. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](#).
73. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2016;2(4):29-33. [links/5711c47508aebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](#).
74. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci*. 2015;4(4):906-910. [https://www.academia.edu/download/38320134/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64



75. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
76. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):28-31.
77. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP)*. 2023;3(2):64-67.
78. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
79. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.  
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
80. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
81. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharmacy Research.* 2014; 391:186-189.
82. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. *Int J Curr Res Biol Med.* 2017;2(2):13-23.DOI: [10.22192/ijcrbm.2017.02.02.003](https://doi.org/10.22192/ijcrbm.2017.02.02.003)
83. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2021 Apr 29;33(27A):36-43.
84. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(7):43-50.
85. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. *Journal of Pharmaceutical Research International.* 2021 Aug 25;33(42A):53-65.
86. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(4):40-4.DOI: [10.22192/ijcrps.2023.10.04.004](https://doi.org/10.22192/ijcrps.2023.10.04.004)

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

87. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. *Int. J. Curr. Res. Med. Sci.* 2023;9(5):31-5.DOI: [10.22192/ijcrms.2023.09.05.005](https://doi.org/10.22192/ijcrms.2023.09.05.005)
88. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, Okafor CJ, Chukwurah EF, Chijioke UO, Amaechi CO. Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. *Journal of Pharmaceutical Research International*. 2021 May 29;33(30A):67-71.
89. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. *Int. J. Curr. Res. Med. Sci.* 2023;9(7):25-8.DOI: [10.22192/ijcrms.2023.09.07.005](https://doi.org/10.22192/ijcrms.2023.09.07.005)
90. Obeagu EI, Bunu UO. Factors that influence unmet need for family planning. *International Journal of Current Research in Biology and Medicine*. 2023;8(1):23-7.
91. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. *International Journal of Advanced Multidisciplinary Research*. 2017;4(8):1-9.DOI: [10.22192/ijamr.2017.04.08.001](https://doi.org/10.22192/ijamr.2017.04.08.001)
92. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
93. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
94. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
95. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-59.
96. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
97. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
98. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
99. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
100. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

101. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
102. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
103. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
104. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
105. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
106. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep*. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
107. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
108. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-11. <http://research.sdpublishers.net/id/eprint/2819/>.
109. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. *International Journal of Current Research in Medical Sciences*. 2018;4(9):41-9.DOI: 10.22192/ijcrms.2018.04.09.006
110. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(8):22-6.DOI: 10.22192/ijcrps.2023.10.08.003
111. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. *Madonna University journal*

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

- of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 2;2(1):134-48.  
<https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40>.
112. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021 Aug 25;33(41B):380-6.
  113. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. *migration*. 2023;17:18.
  114. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. *J. Gynecol. Womens Health*. 2018;8(3):1-4.  
[https://www.academia.edu/download/56538560/A\\_Review\\_on\\_Erythropietin\\_in\\_Pregnancy.pdf](https://www.academia.edu/download/56538560/A_Review_on_Erythropietin_in_Pregnancy.pdf).
  115. Ifeanyi OE. A review on pregnancy and haematology. *Int. J. Curr. Res. Biol. Med*. 2018;3(5):26-8.DOI: [10.22192/ijcrbm.2018.03.05.006](https://doi.org/10.22192/ijcrbm.2018.03.05.006)
  116. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuikie JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. *International Journal of Current Research and Academic Review*. 2015;3(5):376-83.
  117. Ibebuikie JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2017;4(7):28-33.
  118. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A. Evaluation of iron status and some haematological parameters of pregnant women in Enugu, South Eastern Nigeria. *World Journal of Pharmaceutical and Medical Research*. 2021;7(5):251-4.
  119. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. *IOSR Journal of Pharmacy and Biological Sciences*. 2014;9(5):59-64.
  120. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.
  121. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res*. 2023;10(10):56-62.
  122. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickel Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
  123. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
  124. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. *Asian Research Journal of Gynaecology and Obstetrics*. 2022 Dec 14;8(3):12-6.
  125. Vidya S. Sunil Kumar Shango Patience Emmanuel Jakheng, Emmanuel Ifeanyi Obeagu, Emmanuel William Jakheng, Onyekachi Splendid Uwakwe, Gloria Chizoba Eze,

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64

- and Getrude Uzoma Obeagu (2022). Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *International Journal of Research and Reports in Gynaecology.*;5(3):98-105.
126. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. *European Journal of Biomedical.* 2023;10(9):272-5. [links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf](https://doi.org/10.15406/ejbi.2023.10.00272).
  127. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. *Journal of Pharmaceutical Research International.* 2021 Aug 25;33(42A):53-65.
  128. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. *Journal of Pharmaceutical Research International.* 2021 Aug 30;33(42B):39-48.
  129. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(8):22-6.
  130. Obeagu EI, Obeagu GU. Sick Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences.* 2023 Jun 10;6(2):10-3.
  131. Wacleche VS, Tremblay CL, Routy JP, Ancuta P. The biology of monocytes and dendritic cells: contribution to HIV pathogenesis. *Viruses.* 2018;10(2):65.
  132. Orefice R. Immunology and the immunological response in pregnancy. *Best practice & research Clinical obstetrics & gynaecology.* 2021; 76:3-12.
  133. Yu W, Hu X, Cao B. Viral infections during pregnancy: the big challenge threatening maternal and fetal health. *Maternal-Fetal Medicine.* 2022;4(01):72-86.
  134. Mataramvura H, Bunders MJ, Duri K. Human immunodeficiency virus and antiretroviral therapy-mediated immune cell metabolic dysregulation in children born to HIV-infected women: potential clinical implications. *Frontiers in Immunology.* 2023; 14:1182217.

**Citation:** Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*, 2024; 2(1): 47-64